CoChat

The pharmacological management of depression

Open access
Kupfer, David J. · 2005 · Dialogues in Clinical Neuroscience

The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.

Abstract

Depressive disorders are common, recurrent, and chronic, and require treatment A review of the symptom picture and current drug targets demonstrates the need for accurate assessment of depression severity, including suicidality. The initial focus of treatment is rapid resolution of symptoms during an acute phase, followed by continuation. Maintenance treatment is indicated if the risk of recurrence is high. The range of available medications is considerable and the benefit/risk ratio is acceptable. Depression is diagnosable across the life span and treatable at every age (although recent disagreement has arisen with regard to young patients). Comorbidity, both psychiatric and medical, need to be assessed, as does the possible presence of two subtypes of depression (psychotic and bipolar) often requiring different interventions. It is expected that the next generation of antidepressants would be associated with more specific disease and outcome biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.31887/dcns.2005.7.3/dkupfer

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Neuroplasticity and cellular resilience in mood disorders; the multiple influences on neuroplasticity and cellular resilience in mood disorders. Genetic/neurodevelopmental factors, repeated affective episodes, and illness progression might all contribute to the impairments of cellular resilience, volumetric reductions, and cell death/atrophy observed in mood disorders. Stress and depression likely contribute to impairments of cellular resilience by a variety of mechanisms, including reductions in the levels of brain-derived neurotrophic factor (BDNF), facilitating glutamatergic transmission via N-methyl-D-aspartate (NMDA) and nonNMDA receptors, and reducing the cells energy capacity. Neurotrophic factors, such as BDNF, enhance cell survival by activating two distinct signaling pathways: the phosphatidylinositol (Pl)3-kinase pathway, and the extracellular signal-regulated kinase (ERK)-mitogen activated protein (MAP)-kinase pathway. One of the major mechanisms by which BDNF promotes cell survival is by increasing the expression of the major cytoprotective protein, Bcl-2. Bcl-2 attenuates cell death via a variety of mechanisms, including impairing the release of calcium and cytochrome c, sequestering proforms of deathinducing capase enzymes, and enhancing mitochondrial calcium uptake. The chronic administration of a variety of antidepressants increases the expression of BDNF, and its tyrosine kinase receptor (trkB). Lithium and valproic acid (VPA) robustly upregulate the cytoprotective protein Bcl-2. Lithium and VPA also inhibit glucogen synthase kinase (GSK-3b), biochemical effects shown to have neuroprotective effects. VPA also activates the ERK-MAP-kinase pathway, effects that may play a major role in neurotrophic effects and neurite outgrowth. NGF, nerve growth factor; Bcl-2 and Bcl-x, antiapoptotic members of the Bcl-2 family; BAD and Bax, proapoptotic members of the Bcl-2 family; Ras, GTP, Raf, MEK, ERK, components of the ERK-MAP-kinase pathway; CREB, cyclic adenosine monophosphate (cAMP) responsive element binding protein; Rsk-2, ribosomal S-6 kinase; ROS, reactive oxygen species; GR, glucocorticoid receptor; 5-HT, 5-hydroxytryptamine; NE, norepinephrine; P, phosphorylation. Reproduced with permission from reference 9: Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001 ;7:541 -547. Copyright © 2001 Nature Publishing Group.
Figure 1. Neuroplasticity and cellular resilience in mood disorders; the multiple influences on neuroplasticity and cellular resilience in mood disorders. Genetic/neurodevelopmental factors, repeated affective episodes, and illness progression might all contribute to the impairments of cellular resilience, volumetric reductions, and cell death/atrophy observed in mood disorders. Stress and depression likely contribute to impairments of cellular resilience by a variety of mechanisms, including reductions in the levels of brain-derived neurotrophic factor (BDNF), facilitating glutamatergic transmission via N-methyl-D-aspartate (NMDA) and nonNMDA receptors, and reducing the cells energy capacity. Neurotrophic factors, such as BDNF, enhance cell survival by activating two distinct signaling pathways: the phosphatidylinositol (Pl)3-kinase pathway, and the extracellular signal-regulated kinase (ERK)-mitogen activated protein (MAP)-kinase pathway. One of the major mechanisms by which BDNF promotes cell survival is by increasing the expression of the major cytoprotective protein, Bcl-2. Bcl-2 attenuates cell death via a variety of mechanisms, including impairing the release of calcium and cytochrome c, sequestering proforms of deathinducing capase enzymes, and enhancing mitochondrial calcium uptake. The chronic administration of a variety of antidepressants increases the expression of BDNF, and its tyrosine kinase receptor (trkB). Lithium and valproic acid (VPA) robustly upregulate the cytoprotective protein Bcl-2. Lithium and VPA also inhibit glucogen synthase kinase (GSK-3b), biochemical effects shown to have neuroprotective effects. VPA also activates the ERK-MAP-kinase pathway, effects that may play a major role in neurotrophic effects and neurite outgrowth. NGF, nerve growth factor; Bcl-2 and Bcl-x, antiapoptotic members of the Bcl-2 family; BAD and Bax, proapoptotic members of the Bcl-2 family; Ras, GTP, Raf, MEK, ERK, components of the ERK-MAP-kinase pathway; CREB, cyclic adenosine monophosphate (cAMP) responsive element binding protein; Rsk-2, ribosomal S-6 kinase; ROS, reactive oxygen species; GR, glucocorticoid receptor; 5-HT, 5-hydroxytryptamine; NE, norepinephrine; P, phosphorylation. Reproduced with permission from reference 9: Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001 ;7:541 -547. Copyright © 2001 Nature Publishing Group.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 125 references

Research works printed but not linked: 11

  1. Richelson E., 2002, Psychopharmacol Bull., 36, 133
  2. Beck A., 1979, Cognitive Therapy of Depression. New York, NY: Guilford Press;
  3. Goldsmith SK., 2002, Institute of Medicine, National Academy of Sciences: Reducing Suicide, a National Imperative. Washington, DC: The National Academies Press;
  4. Liu B., 1996, Can Med Assoc J., 155, 519
  5. Schulberg HC., 1999, J Clin Psychiatry., 60, S19
  6. Pollock BG., 1999, J Clin Psychiatry., 60, S4
  7. Nierenberg AA., 1990, J Clin Psychiatry., 51, 39
  8. Thase ME., 1995, Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press;, 1081
  9. Paykel ES., 1994, Refractory Depression: Current Strategies and Future Directions. New York, NY: Wiley;, 3
  10. Keller M., 2001, J Am Acad Child Adolesc Psychiatry., 40, 762, 10.1097/00004583-200107000-00010 · DOI · Paper page
  11. Geddes JR., 2002, Depressive Disorders in Adults: Clinical Evidence. London, UK: BMJ Publishing Group;

Cited by

See all 73

Metadata

Authors
Kupfer, D. J.
Affiliations
University of Pittsburgh (US)
Corresponding author
Kupfer, David J.
Venue
Dialogues in Clinical Neuroscience
Published
2005-09-30
Volume
7
Issue
3
Pages
191-205
ISSN
  • 1294-8322 (ISSN-L)
  • 1958-5969
OpenAlex
W16698172
Cited by
69
References
124
Citations by year
2026: 2 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 11 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 1 · 2012: 4
FWCI
1.49
Type
journal article
Language
en
Open access
Locations
  • Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (MH30915)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
depression, pharmacotherapy, antidepressants, depression severity assessment, suicidality, acute phase treatment, continuation treatment, maintenance therapy, recurrence risk, comorbidities, psychotic depression, bipolar depression, young patients, biomarkers, therapeutic target
MeSH terms
Adolescent, Antidepressive Agents, Brain, Child, Depression, Female, Humans, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pharmacological management of depression. https://app.cochat.ai/papers/10.31887/dcns.2005.7.3/dkupfer
The paper
Kupfer, D. J. (2005). The pharmacological management of depression. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2005.7.3/dkupfer

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.